Shanghai Allist Pharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688578.SS

Shanghai Allist Pharmaceuticals Co., Ltd. Revenue for the year ending December 31, 2023: USD 284.26 M

Shanghai Allist Pharmaceuticals Co., Ltd. Revenue is USD 284.26 M for the year ending December 31, 2023, a 147.99% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Revenue for the year ending December 31, 2022 was USD 114.62 M, a 37.40% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Revenue for the year ending December 31, 2021 was USD 83.43 M, a 96,988.64% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Revenue for the year ending December 31, 2020 was USD 85.93 K, a -4.98% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Revenue for the year ending December 31, 2019 was USD 90.43 K, a -86.54% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
SV Wall Street
Shanghai Stock Exchange: 688578.SS

Shanghai Allist Pharmaceuticals Co., Ltd.

CEO Mr. Jinhao Du
IPO Date Dec. 2, 2020
Location China
Headquarters No. 268 Lingxiaohua Road
Employees 1,044
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Shanghai Allist Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in China. It offers pharmaceuticals for the treatment of tumor and cancer diseases. The company was founded in 2004 and is based in Shanghai, China.

StockViz Staff

February 2, 2025

Any question? Send us an email